Researchers and a patient advocate weighed in on current and emerging treatment options for each stage of triple-negative breast...
The first paper to be accepted by the AACR’s latest journal, Blood Cancer Discovery, was published online last week....
The U.S. Food and Drug Administration (FDA) approved a new molecularly targeted therapeutic called fam-trastuzumab deruxtecan-nxki (Enhertu) for treating...
The new year began with the good news that death rates from cancer are continuing their steady decline. A...
Around 400 BC, the Greek physician Hippocrates is believed to have first described tumors as “cancer,” using the words...
In the final days of 2019, the U.S. Food and Drug Administration (FDA) expanded the use of a previously...
In 2019, research continued to drive progress across the spectrum of cancer care in the form of new and...
In November and the first half of December, the U.S. Food and Drug Administration (FDA) announced three approvals for...
As the year winds down, here’s our final edition of Editors’ Picks for 2019. This regular feature highlights one...
Immunotherapeutic advances have dramatically changed the treatment landscape for a host of different cancer types. Notably, immune checkpoint inhibitors...
Editor’s note: When the San Antonio Breast Cancer Symposium (SABCS) kicks off next week, researchers will present the results...